Industry Experts

A genomics and machine-learning leader with over 13 years of experience, Grace has developed breakthrough platforms at the intersection of biology, data, and therapeutics. She is the Co-Founder and CEO of PerturbAI, an AI-native therapeutics company focused on accelerating drug discovery through a systems-level understanding of disease. The company’s platform integrates in vivo Perturb-seq with AI agents and models to map biological circuits directly within intact organisms, enabling a new generation of biological models and therapeutics grounded in causal, in vivo biology.

Previously, Grace served as Vice President of Computational Biology and Machine Learning at ArsenalBio, where she built and led interdisciplinary teams across computational biology, machine learning, and software engineering. During this time, she also led strategic collaborations with partners including Genentech and NVIDIA, driving the generation of large-scale functional genomics datasets and the development of AI models for cell therapy discovery.